Massive Bio announced the launch of "Donation for Life," a new awareness campaign created to support cancer associations and foundations in the United States and Europe.
Massive Bio, which matches cancer patients to clinical trials of innovative new therapies, has launched "Donation for Life," a new awareness campaign to support cancer associations and foundations in the United States and Europe. During the campaign, Massive Bio will select different organizations that support cancer patients to be recipients of donations. The campaign will continue for a year, with updates announced on Massive Bio's website and social media platforms. Massive Bio officials aim to provide thousands of donations by the end of 2023 and hope that "Donation for Life" will inspire other companies to support cancer associations and foundations.
"We believe cancer associations and foundations are vital in educating patients about cancer and specific aspects of the disease, such as participation in clinical trials. That's why we are partnering with these groups to provide them the financial and operational support to accelerate further and expand their efforts," said Selin Kurnaz, chief executive officer and co-founder of Massive Bio. "The burden of cancer is so large that it can't be resolved by one organization, and our role is to be the glue to bring multiple stakeholders together to fight this unfortunate disease together, one patient at a time."
About Massive Bio
Massive Bio empowers cancer patients to find their best treatment options, providing convenient access and enrollment services for oncology clinical trials worldwide, powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to leading-edge therapies, Massive Bio combines its best-in-class AI platform with expertise in genomics, engineering, and data analytics to remove the many barriers to cancer patient enrollment and participation in clinical trials. Headquartered in New York City, Massive Bio is a privately held company that operates in 12 countries.
With Mansion Invest, Mansion turns its members (its guests) into real estate investors & owners by allowing them to invest in the same homes they can book.
MansionLife.com Announces Mansion Invest With Mansion Invest, retail and institutional investors can tap into Mansion's valuable real estate portfolio in an accessible and scalable way.
CHARLOTTE, N.C. - December 22, 2022 - (Newswire.com)
Today, Mansion Group Inc., a Charlotte-based startup founded by investor & retired Red Ventures Chief Digital Officer John Sutton, has come out of stealth mode and announced the development and coming launch of Mansion Invest, the industry's first vertically integrated, fractional single-family home rental real estate investment platform. Invest transforms Mansion's customers into partial property owners by enabling them to own a share of the inspiring homes they can book across the Mansion network.
Mansion will leverage the Mansion Invest platform to expand its network of inspired, flexible, single-family rental homes across the U.S. Through this new platform, Mansion will more than 5x the number of rental homes available to its members by the end of 2023, positioning Mansion to enable its members to seamlessly move across its network of homes as they embark on the next step in their nomadic journeys.
With Mansion Invest, retail and institutional investors can tap into Mansion's valuable real estate portfolio in an accessible and scalable way. Luxury short-term rental homes offer attractive fundamentals, including regularly generated revenue from guest bookings and single-family homes' stability and appreciation profile. Mansion Invest shareholders will have the potential to earn dividend-yielding-passive income with 4% - 8% targeted annual dividends for most offerings, deposited every quarter, PLUS share in any home appreciation in the event of a sale and the tax benefits that come with REIT taxation for most offerings.
The launch of Mansion Invest comes at a moment when investors are increasingly looking to diversify their portfolios after continued public market losses throughout 2022. While the demand to invest in single-family homes remains high due to their stability and appreciation, the soaring interest rates have made the asset class increasingly out of reach for many investors.
"Mansion Invest provides a truly unique investment experience that allows retail investors to make real estate investment decisions in ways similar to how they shop for their own dream homes, hopefully, one that can also create tremendous value for them over time. Unlike others in the category, Mansion Invest will provide access to single-family real estate investments for all retail investors, not just high net-worth accredited investors. By creating an experience that provides them the choice of which homes to become an owner/shareholder in," said John Sutton, Founder of Mansion Group and its primary investor, "Mansion will enable the everyday investor to invest in homes and communities they believe in. We're creating something extraordinary for neighborhoods that can bring the pride of homeownership to the home rental space, something missing from most REITs. Combine this aspect with the ability for our investors to stay in the homes they invest in or allow their friends and family to book easily in the Mansion app, and you create a new class of SFR rentals that are more connected to the spirit of the community and those that live in it."
Mansion Group is working to build tomorrow's single-family rental experience for guests and investors. John Sutton & his co-founders/early investors have invested over $2MM to build the business without traditional venture capital, far less than their peers, reflecting a focus on ensuring the development of a sustainable, long-term business. Mansion has worked tirelessly over the past three years to develop the operational expertise to ensure an excellent guest experience, which leads to outstanding performance for investors in the homes on the Mansion platform. Mansion Group stands out in the fast-growing tech-enabled single-family rental space by vertically integrating and owning 100% of the homes on the platform, essential to providing uncompromising hospitality, next-generation intelligent home technology, and a consistent experience across a wide range of locations in addition to enabling Mansion to provide the platform for retail investors to become owners of the single-family rentals on Mansion.
With over 1,900+ stays managed since launching in early 2019, Mansion Group has experience in the complex single-family rental space unmatched by most tech startups; and experience that has delivered consistently great customers reviews, many of whom highlight "hospitality, quality of the design, and excellent attention to detail" as top reasons for choosing Mansion properties over alternative homes on platforms like Airbnb. Through the Mansion Life app, consumers can book a home with inspiring designs (furnished by the in-house furniture & interior design brand MansionDistrict.com), exceptional amenities, high-quality beds, hotel-grade cleaning, and 24/7 concierge services.
Mansion Group, which began as a real estate investment company and has become a leader in using AI-powered analytics to identify investment homes, owns and operates numerous properties across Charlotte, NC. The company acquired these properties after evaluating them using Mansion's proprietary AI+Human platform, "TheButler," which analyzes thousands of data points such as recent sales, Average Daily Rates of competitors, nearby hotel occupancy, walkability, historical appreciation, submitted development permits, and more to identify target investment homes. By early 2023, Mansion plans to more than double its rental investment properties by expanding into new high-demand cities in the southeast U.S.
The next generation of companies are ones where users are transformed into owners. Introducing ownership to the Mansion platform unlocks access to wealth creation for the average investor and a more significant affinity for the Mansion member experience. In tandem, Mansion opens location expansion, which results in more growth and opportunities for people to enjoy the home rental experience of the future.
Mansion Invest is currently in closed BETA as Mansion works alongside its FINRA-registered Broker Dealer Dalmore Group to register the offering with the SEC, but interested investors can join the waitlist at MansionLife.com; waitlist slots are limited. Questions can be directed to [email protected].
Contact Information:
John Sutton
CEO & Founder [email protected]
8334683789
CRYSTAL RIVER, Fla. - December 22, 2022 - (Newswire.com)
SeaDaddys Nature Center is a tour operator in Crystal River, FL bringing people closer to nature every day for the past 15 years. This week, they announce the opening of the Seadaddys Nature Adventure Center.
The Center is born out of our mission to raise conservational awareness, including seagrass education and protection, manatee and wildlife education thru hands on interactions and educational programs, explains Candi Milby, Owner & Founder of the SeaDaddys Nature Center.
SeaDaddys Nature Adventure Center helps to educate, and provide fun, and interactive experiences including:
A Model of the Florida Wetlands - Seadaddys Nature Center project begins with a forest landscape through Florida marsh lands/wetlands to mangroves, gulf Mexico and all the way to Florida's Natural Springs and its wildlife, with informational nuggets all along.
Training & Classes - SeaDaddys Adventure Center offers diving classes in Crystal River. Diving for science is a critical part of studying and maintaining a healthy under water world, its wildlife and ecosystems. Name brand gear sales are available too.
Seagrass Lab - In the seagrass lab, they grow the seagrass and offer it at no cost for replanting locally and beyond, to organizations willing to do the work of replanting so that other likeminded wildlife educators in our area can be part of the program.
Walking & Boat Tours Available - Experience nature in multiple ways; by walking through our indoor nature themed display. Learn from our manatee education programs and Crystal River Manatee swim tours wildlife viewing. Also, don't miss the worlds best guided scalloping tours!
Futuristic Experiences - Even more exciting, is what they are working on next, which is AR and VR experiences that are planning to be launched by Nov 2023.
Being a conservationist, the new Seadaddys Nature Adventure Center used over 70% of materials that were either upcycled, used items, or repurposed and more than 80% of building debris where also recycled or repurposed. More than 90 % of all materials needed or used was purchased within the City of Crystal River, FL.
For the past 15 years we have hosted thousands of people from all over the globe to go Swimming with Manatees, Get their Diving Certifications, Scalloping and nature conservation. Come on out and explore something new season with a hands on experience you will never forget. We located at 308 SE US Hwy 19, Crystal River, FL 34429, (352) 794-6362, https://www.naturesadventurecenter.com.
Contact Information:
Candi Milby
Owner of Seadaddys Nature Adventure Center [email protected]
(352) 794-3452
Exmark Original Series highlights top landscape contractors across the country
Exmark Signature Stories, ProQual Landscaping Tempe, AZ-based ProQual Landscaping focuses on maintaining the landscaping of large-scale and master-plan developments in the Phoenix metro area.
BEATRICE, Neb. - December 22, 2022 - (Newswire.com)
Exmark has launched a new episode of its Signature Stories video series, which highlights the landscape maintenance professionals that rely on the company's mowers. Signature Series episodes offer a look inside the day-to-day operations of some of the top lawn care professionals across the country.
Exmark Director of Marketing, Jamie Briggs, said the Signature Stories videos demonstrate the commitment landscape maintenance professionals must have to run a successful business.
"At Exmark, we're honored to work with some of the best landscape professionals across the country, and we see how hard they work every day," Briggs said. "That's why we're focused on building the mowers these professionals need to do their jobs faster and more efficiently.
"Whether it's the next evolution of an established product, or an all-new product innovation, Exmark is committed to building equipment that gives them a competitive advantage today, tomorrow, and into the future."
In the fifth Exmark Signature Stories episode, the Exmark crew travels to Tempe, AZ, to visit Scott Needham and his crew at ProQual Landscaping. With a focus on large-scale and master-plan communities in the greater Phoenix area, ProQual crews are on the ground every day in the neighborhoods they serve. This daily interaction helps them better understand the unique needs and expectations of each customer and consistently gives them what they're looking for.
Needham and the ProQual team have relied on Exmark mowers for nearly 18 years. Today, with its crews mowing more than 500 acres each week of the year, ProQual counts on the productivity and reliability Exmark mowers deliver. By investing in the right employees and equipment, ProQual empowers its teams to work with efficiency, speed, and precision. This has helped the company grow and serve more clients, while also providing increased opportunities for employee growth.
View each of the new Exmark Signature Stories videos on Exmark's website at Exmark.com/stories.
# # #
About Exmark Exmark Manufacturing was incorporated in May 1982 as an independent manufacturer of professional turf care equipment. Today, it is the leading manufacturer of commercial mowers and equipment for the landscape professional. In addition to designing, building, and marketing quality turf care equipment, Exmark's goal is total customer satisfaction. All Exmark products are designed to help customers increase productivity while delivering unmatched quality. Products are sold to distributors and dealers who share the company's commitment to customer service and quality products. Learn more at Exmark.com.
Contact Information:
Matt Gersib
Public Relations, Exmark [email protected]
(402) 314-2150
WINSTON-SALEM, N.C. - December 22, 2022 - (Newswire.com)
Candyoni Maison is bringing honesty, humor, and eroticism back to the boudoir with the launch of their Luxury Erotic Lickable Oils.
Just in time for the New Year, the straight-talking edible oïl company has created a massive, exciting range of lickable oils, with cheeky names like The Forbitten Pie™, Cinnamon Toast Lunch™, and 27 more. Described as Luxury Erotic Lickable Oils, each 30ml glass bottle is made in the US and filled with the finest natural ingredients and flavorings.
Bringing a smile and a laugh back to the bedroom, Candyoni Maison describes their 'Elixirs' coquettishly as a range of vibrant flavors with baked-in nostalgia. Lucky Green Apple™ transports customers to the taste of candy apples at the fairground, while 50 Shades of Salted Caramel™ is reminiscent of hot summers.
Candyoni Maison's mission is to encourage consenting adults to talk openly, laugh and enjoy their foreplay. The sexy startup company believes that in exploring sex - whether coupled or solo, edible oils designed with love and care to delight and please should be included.
Here's the science bit. All arousal originates in the brain where input from touch, vision and sound combines with taste to entice. Often understated, taste and smell are major factors that get the engine running. Both men and women experience different levels of stimulation based on the density and number of taste buds on their tongues.
With brands like The Swimwear Branding Agency, Candyoni Maison's Luxury Erotic Lickable Oils is the second brainchild of Creative Director and CEO Stephanie Perry. Founded in early 2022, the process to create the perfect flavors has been a long, exciting, and enjoyable journey. Explaining a little about the process up to this point Perry said, "I love the feedback from our clients, and their stories. I love the happiness our oils bring." But now the feedback is in, and the beta testing is done, she's delighted to launch the final products. Unable to hide her delight she explained, "We're thrilled to introduce our lickable oils to the world!"
For Perry and the team at Candyoni Maison, sex, sexuality and empowerment should be talked about openly by women and men. Communication around sex is key to a healthy sex life. As a female-founded business Candyoni Maison understands the prevalence of internalized sexual hang-ups. But as a brand, they are keen to challenge both men and women everywhere to be bold.
The ultimate multi-sensory experience is coming to a bedroom near you - New Year's Day 2023. In-stock orders ship starting Jan. 9. Order today and you'll be enraptured with anticipation.
Use code 'Lick' at www.Candyoni.Maison for 25% off your first order. Gift cards excluded.
ENDS
Editors notes: To learn more contact Candyoni Maison at [email protected] or visit www.Candyoni.Maison.
The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers
While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used today has gone largely unchanged in the last century. Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, is developing one of the first microdosing systems that aims to improve the overall patient experience and streamline practice flow by facilitating digital delivery of eye medications.
The investigational delivery device is currently only used in clinical study settings and has shown promise in delivering cleaner and more efficient ocular drug delivery. "The proprietary Eyenovia device takes a novel approach to administering eye medication via microdosing and does it in a way that should improve the patient experience," said Michael Rowe, CEO of Eyenovia. "Traditional eye droppers are cumbersome, inaccurate, and prone to contamination. Even when handled with care, there's still a significant likelihood that medication patients are paying for gets wasted due to missing drops."
The device is uniquely designed with no protruding parts and a recessed nozzle to not touch patients' eyes, reducing the likelihood of infection. Eyenovia also expects a more gentle dosing experience to create a fundamental paradigm shift in eye care.
Eye drop innovation has stagnated, in part due to changing medical device regulations that complicate patient access to innovative devices. Safety takes precedence in the medical device industry; however, as digital innovation leaps ahead of bureaucratic regulatory bodies, regulators are challenged to keep pace with the cutting-edge new products that push the boundaries of technology.
While the world of healthcare looked significantly different 100 years ago, similar paradigm shifts in medical technology through innovations like pacemakers, cochlear implants, 3-D printed body parts, and artificial hearts revolutionized their respective industries, greatly improving quality of life and patient care. With a market share valued at roughly €100 billion in Europe, medical devices make up 7.5% of healthcare expenditure in most publicly funded healthcare systems, and the American ecosystem is taking notice.
As American private venture capital makes inroads into the digital health market, the total capital investment in medical devices has increased by a factor of five, which portends a promising future for improved patient care. Medical technology device advancement is only expected to increase over the next five years, and Eyenovia is one of those industry leaders in championing innovation.
"We're proud to be innovating in this space where we have the potential to make lives easier for millions of Americans and people worldwide suffering from chronic eye conditions," adds Rowe.
Eyenovia, Inc. is a pre-commercial ophthalmic technology company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.
JACKSONVILLE, Fla. - December 22, 2022 - (Newswire.com)
Generation USA, a national workforce development nonprofit, honored graduates on Nov. 2, 2022, its first in-person ceremony since the onset of the COVID-19 pandemic, in Jacksonville, FL. The event celebrated 17 virtual and in-person graduates of the Credit Union Members Service Specialist and Assistant Medical Administrative Generation training programs while commemorating the organization's new offices and classroom space in the Beaver Street Enterprise Center.
"It takes confidence and a belief in yourself to get you to this moment, but to the next moment, it takes everyone else's belief in you," said Samantha Beeler, President of the League of Southeastern Credit Union and Affiliates, during her address as Keynote Speaker for the event. "The secret sauce is how today came together, in that a lot of people believed in you."
Other attendees of the graduation ceremony included Career Source Northeast Florida and local business and community partners. After the ceremony, Generation provided a tour of its new Administrative wing, Student Center, conference room, and classrooms for in-person learning and meetings. Designers tailored the space to meet Generation's unique specifications thanks to financing provided by the Local Initiatives Support Corporation, a strong promoter of economic development throughout Jacksonville's Rail Yard District, where the offices are situated.
The Beaver Street Enterprise Center opened in 2003 as an initiative of the nonprofit FreshMinistries, Inc., which focuses on worldwide job training, health, and entrepreneurship. It offers space and resources to more than 50 entrepreneurs in two buildings, as well as technical support to hundreds of offsite small business owners. Generation's 4,000 square feet of office space occupies the last unfinished portion of the Beaver Street Enterprise Center's 15,000-square-foot building at 728 Blanche Street.
"We are very pleased to welcome Generation USA to Beaver Street," said Beaver Street Enterprise Center Executive Director Terrance Brisbane. "Its focus on workforce development across a broad range of fields contributes in powerful ways to companies large and small throughout Florida. Our organizations work to help individuals and businesses thrive, and we will do all we can to support Generation's efforts in Jacksonville."
Generation USA is a national workforce development nonprofit offering free online job training to help individuals thrive in what can be inaccessible careers for some. Its training and free technical education programs provide students with the skills and knowledge necessary to earn jobs in medical administration, digital marketing, web development, and credit services. To learn more about the organization's mission and how it is helping to build a qualified Generation Now Network for the up-and-coming youth demographic, visit https://usa.generation.org/.
About Generation
Generation is a nonprofit that transforms education into employment systems to prepare, place and support people into life-changing careers that would otherwise be inaccessible. The global pandemic has led to an unprecedented surge in unemployment. Even before the pandemic, more than 75 million young adults were out of work globally and three times as many were underemployed — and 375 million workers of all ages needed to learn new skills by 2030. At the same time, certain jobs remain in high demand, and 40 percent of employers say a skills shortage leaves them with entry-level vacancies. To date, more than 38,000 people have graduated from Generation programs, which prepare them for meaningful careers in 14 countries. Generation works with more than 3,900 employer partners and many implementation partners and funders. For more, visit usa.generation.org.
NEWARK, Calif. - December 22, 2022 - (Newswire.com)
EyeQue, the leader in innovative vision testing is proud to announce the donation of 25,000 Personal Vision Trackers to the Oklahoma City Indian Clinic. EyeQue is proud to be able to give back to communities, especially during the most giving time of the year.
The Oklahoma City Indian Clinic is a 501(c)(3) non-profit established in 1974 to provide excellent health care and wellness services to American Indians in central Oklahoma. The clinic staff cares for more than 22,000 patients from over 200 federally recognized tribes annually. American Indians can receive a range of services, including medical, dental, pediatrics, prenatal, pharmacy, optometry, physical fitness, nutrition, family programs and behavioral health services.
"The use of EyeQue devices will help us meet the vision needs of our growing patient population," said Monica McKee, OKCIC's Vice President of Ancillary Clinical Services.
"EyeQue's solutions allow people to self test their vision, from anywhere at any time. We are delighted to work with and support the OKCIC community in using our technology to improve health care for Native American patients," said Dr. John Serri, Founder and CEO of EyeQue.
"It's important to pay attention to any changes in your vision," said Byron Bonner, OD, OKCIC's Pediatric Optometrist. "At-home vision tests provide greater accessibility for our patients to monitor their vision, and catch any concerning changes early."
EyeQue believes that clear vision is a right, not a privilege. The company works hard at developing easy to use self-testing ophthalmic medical technologies.
The Company founded in 2015, headquartered in Silicon Valley is dedicated to putting accurate vision tests directly into the hands of people around the world. Based on MIT and EyeQue's own patented technologies, EyeQue's intelligent vision solutions allow people anywhere to self-administer an expanding portfolio of accurate and low cost vision tests using simple passive optical devices, free IOS and Android mobile applications, and a secure HIPAA cloud-based processing and service center.
Contact Information:
John Serri
CEO and Co-Founder [email protected]
510-585-7982
Nicole Skibinski
VP of Business Development [email protected]
510-399-5801
Technology developer to create continuing education courses on incorporating UV disinfection into building design.
ORLANDO, Fla. - December 22, 2022 - (Newswire.com)
The challenge of providing people with safe, clean working and living spaces during the COVID-19 pandemic will make health and hygiene central concerns in the future of building design. With accreditation from the American Institute of Architects (AIA) in 2023, Violet Defense will create courses to educate architects on how they can incorporate UV disinfection technology into their core designs for sustainable buildings.
Violet Defense is an ultraviolet disinfection technology company founded in 2012 and the developer of patented pulsed xenon UV disinfection technology, proven in multiple independent lab tests to kill pathogens, including E. coli, salmonella, S. aureus, C. diff, MRSA, norovirus, coronavirus and SARS-CoV-2.
The concept of incorporating UV technology into facility designs is still relatively new. Since 2020, facility owners and managers have begun to retroactively install UV disinfection systems to improve cleanliness and provide a hygienic environment. However, architects have had little guidance on how to include the technology during the design stage and face a significant hurdle.
For every element in their plans, architects must identify to what specification class it belongs. At this time, UV technology does not fall under any particular specification, with the closest correlation being HVAC purification.
"We believe that, rather than seeing this as an impediment, architects should see this as an opportunity to be among the first to break into a new area of construction design, one that incorporates health and wellness from the very beginning," said Bruce Mosley, President of Violet Defense. "With AIA certification, we will create courses that will help architects incorporate UV disinfection technology into their designs right from the start."
Architects with AIA certification are required to take a certain number of AIA-accredited courses within a year in order to maintain that certification. Violet Defense will be developing both in-person and online course offerings.
UV disinfection provides multiple advantages over conventional cleaning methods, such as automation, making it simple and easy for facility managers to schedule and maintain. UV disinfection also is chemical-free, reducing supply costs and the toxic effects of powerful cleansers. Studies also show UV disinfectant to be superior to manual cleaning, enabling disinfection of pathogens in the air and on high-touch surfaces.
Violet Defense technology already is in wide use nationwide, including hotels, convention centers, colleges and schools, and amateur and professional sports training facilities.
About Violet Defense Violet Defense is dedicated to UV disinfection solutions for a brighter, healthier, more sustainable future. Violet Defense provides trusted and efficient UV disinfection solutions that are sustainable, cost-effective, and protect the places you live, learn, work, and play. We are committed to your well-being and strive to give you confidence and peace of mind wherever you go. To learn more about Violet Defense and its initiatives, visit www.violetdefense.com, or follow us on Facebook or on LinkedIn (@violetdefense).
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects related to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses.
The global anti-inflammatory therapeutics market size was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is expected to hit USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. One key differentiator of Gb Sciences' CRS therapeutic is the early-intervention and preventative opportunities for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapeutic may also be useful for patients who are experiencing CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T-cells.
"Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of certain viruses. Our cannabis-inspired therapeutics were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself," said Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.
Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures that were designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses, while preserving the immune functions and cytokines necessary to fight viral infections. Gb Sciences recently published a white paper on their novel development program titled "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics"; download it here.
A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences' proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers. Gb Sciences' MEM, containing either two or three cannabinoids each, reduced the levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the single ingredients tested separately. The ratios of those cannabinoid molecules within the MEM formulations also greatly influenced their anti-inflammatory potential, the study reported.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes," and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
